Cross-Sector entity
D.C. Circuit Court is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Each carries 1 original source on average.
4 verified stories tracked
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
D.C. Circuit Court is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Each carries 1 original source on average. We currently track 4 Cross-Sector stories that mention Whitney Economics, all published on July 12, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Whitney Economics. Shared-story counts are live from our verified record — not editorial picks.
Investors are watching the D.C. Circuit case closely as MMJ International Holdings claims marijuana rescheduling would deliver over $2 billion in annual tax savings to multi-state operators, potentially boosting profitability and stock prices.
MMJ International Holdings' latest filing reveals that up to $2.24 billion in annual 280E tax overpayments could be reversed, plus $1.6B in accrued unpaid taxes forgiven—a sum that would transform balance sheets for cash-strapped cannabis startups.
The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling.
Source: finanznachrichten.de
